Emergent BioSolutions Inc. has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5 million to develop monoclonal antibody therapeutics for viral hemorrhagic fever.
The company announced the order in a Feb 13 press release.
Using monoclonal antibodies from Mapp Biopharmaceutical Inc., the company will conduct technology transfer of process materials and information, perform process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance.
This task order will utilize Emergent’s Center for Innovation in Advanced Development and Manufacturing (CIADM) facility located in Baltimore, Maryland. The task order consists of a 36-month period of performance with a base task order valued at $7.4 million and options that, if executed, will bring the total task order value over three years to up to $30.5 million.
This is the fourth BARDA Task Order awarded to Emergent under the CIADM program. Since its inception in 2012, Emergent’s CIADM facility has been utilized to respond to public health emergencies including Ebola and Zika.
